Paper41774209
Computer-aided drug design in acute myeloid leukemia: a comprehensive review of advances, challenges, and future prospect.
Hao L and 7 others. J Comput Aided Mol Des, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Computer-aided drug design in acute myeloid leukemia: a comprehensive review of advances, challenges, and future prospect. Papers, record 41774209. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41774209
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Computer-aided drug design in acute myeloid leukemia: a comprehensive review of advances, challenges, and future prospect.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Computer-Aided Design | Major topic |
| Drug Design | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Molecular Docking Simulation | |
| Molecular Dynamics Simulation | |
| Artificial Intelligence | |
| fms-Like Tyrosine Kinase 3 | |
| Ligands | |
| Protein Kinase Inhibitors | |
| Drug Discovery |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2025NSFSC2167 | Sichuan Science and Technology Program of China | PubMed |
Source PubMed
References120
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33902106 | Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. | Nature | 2021 | https://conductscience.org/library/papers/33902106 | PubMed |
| 2 | 22409994 | Drug resistance: still a daunting challenge to the successful treatment of AML. | Drug Resist Updat | 2012 | https://conductscience.org/library/papers/22409994 | PubMed |
| 3 | 39726698 | A hitchhiker's guide to deep chemical language processing for bioactivity prediction. | Digit Discov | 2025 | https://conductscience.org/library/papers/39726698 | PubMed |
| 4 | 27391254 | Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times. | J Med Chem | 2016 | https://conductscience.org/library/papers/27391254 | PubMed |
| 5 | 26077712 | Accurately modeling nanosecond protein dynamics requires at least microseconds of simulation. | J Comput Chem | 2016 | https://conductscience.org/library/papers/26077712 | PubMed |
| 6 | 30651634 | Targeting FLT3 mutations in AML: review of current knowledge and evidence. | Leukemia | 2019 | https://conductscience.org/library/papers/30651634 | PubMed |
| 7 | 39300079 | Current status and research directions in acute myeloid leukemia. | Blood Cancer J | 2024 | https://conductscience.org/library/papers/39300079 | PubMed |
| 8 | 37838760 | The maximal and current accuracy of rigorous protein-ligand binding free energy calculations. | Commun Chem | 2023 | https://conductscience.org/library/papers/37838760 | PubMed |
| 9 | 30651561 | Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. | Nat Commun | 2019 | https://conductscience.org/library/papers/30651561 | PubMed |
| 10 | 26205061 | Molecular docking and structure-based drug design strategies. | Molecules | 2015 | https://conductscience.org/library/papers/26205061 | PubMed |
| 11 | 36237321 | Targeted therapy in NPM1-mutated AML: Knowns and unknowns. | Front Oncol | 2022 | https://conductscience.org/library/papers/36237321 | PubMed |
| 12 | 34790902 | Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. | Nat Cancer | 2021 | https://conductscience.org/library/papers/34790902 | PubMed |
| 13 | 25837374 | Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220). | PLoS One | 2015 | https://conductscience.org/library/papers/25837374 | PubMed |
| 14 | 9389713 | CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. | Blood | 1997 | https://conductscience.org/library/papers/9389713 | PubMed |
| 15 | 38913862 | ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. | Bioinformatics | 2024 | https://conductscience.org/library/papers/38913862 | PubMed |
| 16 | 23291630 | ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. | Nat Med | 2013 | https://conductscience.org/library/papers/23291630 | PubMed |
| 17 | 39078434 | Significance of targeting DNMT3A mutations in AML. | Ann Hematol | 2025 | https://conductscience.org/library/papers/39078434 | PubMed |
| 18 | 29186125 | Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. | Nature | 2017 | https://conductscience.org/library/papers/29186125 | PubMed |
| 19 | 29139324 | Molecular dynamics simulations and novel drug discovery. | Expert Opin Drug Discov | 2018 | https://conductscience.org/library/papers/29139324 | PubMed |
| 20 | 27326911 | Descriptors and their selection methods in QSAR analysis: paradigm for drug design. | Drug Discov Today | 2016 | https://conductscience.org/library/papers/27326911 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41774209
GET https://conductscience.org/api/papers/v1/41774209/references?page=2